Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

TooManyPeaks identifies drug-resistant-specific regulatory elements from single-cell leukemic epigenomes [ChIP-seq]

ABSTRACT: TooManyPeaks identifies drug-resistant-specific regulatory elements from single-cell leukemic epigenomes [ChIP-seq]

PROVIDER: PRJNA718323 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR14097425_1.fastq.gz	Fastqsanger.gz
	SRR14097425_2.fastq.gz	Fastqsanger.gz
	SRR14097426_1.fastq.gz	Fastqsanger.gz
	SRR14097426_2.fastq.gz	Fastqsanger.gz
	SRR14097427_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

TooManyPeaks identifies drug-resistant-specific regulatory elements from single-cell leukemic epigenomes [ATAC-seq]

Project description:TooManyPeaks identifies drug-resistant-specific regulatory elements from single-cell leukemic epigenomes [ATAC-seq]

| PRJNA656191 | ENA

TooManyPeaks identifies drug-resistant-specific regulatory elements from single-cell leukemic epigenomes.

Project description:Emerging single-cell epigenomic assays are used to investigate the heterogeneity of chromatin activity and its function. However, identifying cells with distinct regulatory elements and clearly visualizing their relationships remains challenging. To this end, we introduce TooManyPeaks to address the need for the simultaneous study of chromatin state heterogeneity in both rare and abundant subpopulations. Our analyses of existing data from three widely used single-cell assays for transposase-accessible chromatin using sequencing (scATAC-seq) show the superior performance of TooManyPeaks in delineating and visualizing pure clusters of rare and abundant subpopulations. Furthermore, the application of TooManyPeaks to new scATAC-seq data from drug-naive and drug-resistant leukemic T cells clearly visualizes relationships among these cells and stratifies a rare "resistant-like" drug-naive sub-clone with distinct cis-regulatory elements.

| S-EPMC8409102 | biostudies-literature

TooManyPeaks identifies drug-resistant-specific regulatory elements from single-cell leukemic epigenomes [ATAC-seq]

Project description:Purpose: To characterize epigenomic heterogeneity in GSI-responsive and -resistant T-ALL cells Method: We generated GSI-resistant T-ALL DND41 cells and profiled their epigenome using single-cell RNA sequencing. Result: We report here the presence of resistant-like subpopulation in drug naïve DND41 T-ALL cells. Conclusion: While other popular scRNA-seq clustering algorithms failed, TooManyPeaks, a suite of clustering and visualization algorithm developed in our lab, could identify rare resistant-like DND41 T-ALL cells.

2023-08-07 | GSE155916 | GEO

TooManyPeaks identifies drug-resistant-specific regulatory elements from single-cell leukemic epigenomes [ChIP-seq]

Project description:Purpose: To investigate the impact of GSI resistance on epigenome of Notch-mutated T-ALL Methods: We generated scATAC-seq and H3K27ac ChIP-seq in parental and GSI-resistant cells Results: Using TooManyPeaks, a novel algorithm for scATAC-seq analysis, we identified subpopulation of epigenetically resistant-like parental cell.

2023-08-07 | GSE171098 | GEO

Rat oocyte epigenomes

Project description:Rat oocyte epigenomes

| PRJNA769697 | ENA

Invalidation of a novel marker for therapy-resistant leukemic stem cells responsible for relapse in patients and PDX

Project description:Drug tolerant leukemic cell stem (LSC) subpopulations may explain frequent relapses in acute myeloid leukemia (AML), suggesting that these Relapse-Initiating Cells (RICs) persistent after chemotherapy represent bona fide targets to prevent drug resistance and relapse. We uncover that the G-protein coupled receptor CALCRL is expressed in RICs, and that the overexpression of CALCRL and/or of its ligand adrenomedullin (ADM) and not CGRP correlates to adverse outcome in AML. CALCRL knockdown impairs leukemic growth, decreases LSC frequency and sensitizes to cytarabine in patient-derived xenograft models.

2020-12-14 | GSE162628 | GEO

RNAi profiling of primary human AML cells identifies ROCK1 as a therapeutic target and nominates Fasudil as an anti-leukemic drug.

Project description:Acute myeloid leukemia (AML) is characterized by a marked genetic heterogeneity, which complicates the development of novel therapeutics. The delineation of pathways essential within the patient-individual mutational background might overcome this limitation and facilitate personalized treatment. We report the results of a large-scale lentiviral loss-offunction RNA-interference-(RNAi)-screen in primary leukemic cells. Stringent validation identified six genes (BNIPL1, ROCK1, RPS13, STK3, SNX27, WDHD1) whose knockdown impaired growth and viability of the cells. Dependence on these genes was not caused by mutation or overexpression and while some of the candidates seemed to be rather patientspecific, others were essential in cells isolated from other AML patients. In addition to the phenotype observed after ROCK1 knockdown, treatment with the approved ROCK-inhibitor fasudil resulted in increased apoptosis and decreased viability of primary AML cells. In contrast to observations in some other malignancies, ROCK1-inhibition did not foster growth of immature malignant progenitors; but was also toxic to this cell fraction in feeder-co-culture and xenotransplantion experiments, indicating a distinct effect of ROCK1 inhibition on leukemic progenitors. We conclude that large scale RNAi screens in primary patient-derived cells are feasible and can complement other methods for personalized cancer therapies, such as expression and mutation profiling. Large-scale lentiviral loss-of-function shRNA screen in primary leukemic cells with two time points, exome sequencing of primary leukemic cells, and a gene expression profiling of primary cells from four leukemic and three healthy samples.

2015-05-16 | E-GEOD-68925 | biostudies-arrayexpress

Leukemic hematopoiesis

Project description:Leukemic hematopoiesis

| PRJNA881262 | ENA

Drug-tolerant cancer cell persisters survive lethal exposures by silencing transposable elements [ChIP-Seq]

Project description:Establishing and maintaining phenotypic heterogeneity within cell and organismal populations is an evolutionarily conserved strategy that ensures survival of the population following stressful exposures. We previously identified a transient, reversible, drug-tolerant cancer cell subpopulation that survives otherwise lethal drug exposures. Here we show that these drug-tolerant persisters (DTPs) assume a highly heterochromatic state, which requires factors that modify or bind trimethylated H3 lysine 9 (H3K9me3). The increased H3K9me3 in DTPs is largely restricted to evolutionarily young Long Interspersed Repeat elements (LINEs). This transcriptionally repressive state, which decreases the expression of these retrotransposable elements, is critical for DTP survival, and disruption of this heterochromatic state results in re-expression of LINE elements and ablation of this subpopulation. Together, these findings establish a role for epigenetic silencing of transposable elements as a population survival strategy to maintain genomic integrity in subpopulations of cancer cells during lethal drug exposures.

2017-07-03 | GSE74179 | GEO

Drug-induced cis-regulatory elements in human hepatocytes affect molecular phenotypes associated with drug efficacy and adverse reactions

Project description:We conducted a quantitative assessment of drug-inducible cis-regulatory elements (CREs) based on transcription initiation profiling of mRNAs and noncoding RNAs, including enhancer RNAs, by using CAGE (Cap Analysis of Gene Expression). Candidate CREs were identified in a hepatocellular carcinoma HepG2 cell line with stable expression of drug-responsive transcription factor pregnane X receptor (PXR) .

2024-07-24 | GSE272109 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data